Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES DEBT SETTLEMENT AGREEMENTS

Ventripoint Diagnostics Ltd. has agreed to settle an aggregate of $542,591.50 of debt owed to certain arm's-length creditors of the corporation by issuing an aggregate of 5,425,915 common shares of the corporation at a price of 10 cents per share.

The shares are subject to a hold period of four months and one day. The corporation determined to satisfy the indebtedness with shares in order to preserve its cash for development of its business. Issuance of the shares is subject to approval by the TSX Venture Exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.